STAT+: From an elixir for ‘little hotheads’ to deadly overdoses, how Tylenol became a medicinal scapegoat

Megan Molteni explores groundbreaking findings at the intersection of genomic medicine, neuroscience, and reproductive technology. She has been part of STAT since 2021, having previously covered health and science for WIRED. You can contact Megan via Signal at mmolteni.13.

Seventy years have passed since McNeil Laboratories, based in Philadelphia, launched the first pure acetaminophen product in the United States: Elixir Tylenol, a prescribed medication for pain and fever in children. Marketed as “for little hotheads,” this innovative medicine was presented in a charming red carton shaped like a fire engine, capturing the hearts of parents and children alike.

Over the decades, Tylenol has emerged as one of the most widely consumed medications globally. However, its safety has come under scrutiny periodically, most recently when President Trump publicly advised pregnant women to avoid Tylenol, suggesting without substantial scientific support a possible connection to autism.

It is intriguing that a product with such extensive use could become a target for public skepticism. Trump’s comments during an extraordinary press conference on Monday sparked significant backlash from medical associations, autism advocacy groups, and pediatric experts. The history of acetaminophen is filled with twists and turns, dating back centuries to the use of the bark from the Cinchona tree by indigenous populations in Peru for treating fevers. Along this journey, concerns about its safety have surfaced—sometimes justified, but often exaggerated. This tangled narrative fosters a certain level of confusion that enables the rise of conspiratorial attitudes within the Make America Health Again movement, which is gaining political traction.